SLE
MCID: LPS004
MIFTS: 69

Lupus Erythematosus (SLE)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lupus Erythematosus

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 76 53 55 15 73
Lupus 12 53 43 3 15
Subacute Cutaneous Lupus 53 73
Disseminated Lupus Erythematosus 53
Lupus Erythematosus, Systemic 73
Systemic Lupus Erythematosus 53
Lupus Erythematosus, Discoid 73
Lupus Vulgaris 73
Discoid Lupus 53
Sle 53

Classifications:



External Ids:

Disease Ontology 12 DOID:8857
ICD10 33 L93 L93.0
ICD9CM 35 695.4
NCIt 50 C27153

Summaries for Lupus Erythematosus

MedlinePlus : 43 What is lupus? Lupus is an autoimmune disease. This means that your immune system attacks healthy cells and tissues by mistake. This can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. There are several kinds of lupus Systemic lupus erythematosus (SLE) is the most common type. It can be mild or severe, and can affect many parts of the body. Discoid lupus causes a red rash that doesn't go away Subacute cutaneous lupus causes sores after being out in the sun Drug-induced lupus is caused by certain medicines. It usually goes away when you stop taking the medicine. Neonatal lupus, which is rare, affects newborns. It is probably caused by certain antibodies from the mother. Who gets lupus? Anyone can get lupus, but women are most at risk. Lupus is two to three times more common in African American women than in Caucasian women. It's also more common in Hispanic, Asian, and Native American women. African American and Hispanic women are more likely to have severe forms of lupus. What causes lupus? The cause of lupus is not known. What are the symptoms of lupus? Lupus can have many symptoms, and they differ from person to person. Some of the more common ones are Pain or swelling in joints Muscle pain Fever with no known cause Red rashes, most often on the face (also called the "butterfly rash") Chest pain when taking a deep breath Hair loss Pale or purple fingers or toes Sensitivity to the sun Swelling in legs or around eyes Mouth ulcers Swollen glands Feeling very tired Symptoms may come and go. When you are having symptoms, it is called a flare. Flares can range from mild to severe. New symptoms may appear at any time. How do I know if I have lupus? There is no single test to diagnose lupus, and it's often mistaken for other diseases. So it may take months or years for a doctor to diagnose it. Your doctor may use many tools to make a diagnosis: Medical history Complete exam Blood tests Skin biopsy (looking at skin samples under a microscope) Kidney biopsy (looking at tissue from your kidney under a microscope) What are the treatments for lupus? There is no cure for lupus, but medicines and lifestyle changes can help control it. People with lupus often need to see different doctors. You will have a primary care doctor and a rheumatologist (a doctor who specializes in the diseases of joints and muscles). Which other specialists you see depends on how lupus affects your body. For example, if lupus damages your heart or blood vessels, you would see a cardiologist. Your primary care doctor should coordinate care between your different health care providers and treat other problems as they come up. Your doctor will develop a treatment plan to fit your needs. You and your doctor should review the plan often to be sure it is working. You should report new symptoms to your doctor right away so that your treatment plan can be changed if needed. The goals of the treatment plan are to Prevent flares Treat flares when they occur Reduce organ damage and other problems Treatments may include drugs to Reduce swelling and pain Prevent or reduce flares Help the immune system Reduce or prevent damage to joints Balance the hormones Besides taking medicines for lupus, you may need to take medicines for problems that are related to lupus such as high cholesterol, high blood pressure, or infection. Alternative treatments are those that are not part of standard treatment. At this time, no research shows that alternative medicine can treat lupus. Some alternative or complementary approaches may help you cope or reduce some of the stress associated with living with a chronic illness. You should talk to your doctor before trying any alternative treatments. How can I cope with lupus? It is important to take an active role in your treatment. It helps to learn more about lupus - being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe. It is also important to find ways to cope with the stress of having lupus. Exercising and finding ways to relax may make it easier for you to cope. A good support system can also help. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus 16 and neonatal lupus erythematosus, and has symptoms including seizures, pruritus and exanthema. An important gene associated with Lupus Erythematosus is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Simvastatin and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and b cells, and related phenotypes are Decreased viability and Decreased viability

NIH Rare Diseases : 53 Lupus is an autoimmune disease that can affect almost every organ in the body. Symptoms of lupus can range from very mild to life-threatening. There are three main types of lupus; systemic lupus erythematosus, discoid lupus, and drug-induced lupus. Symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. Genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors. Studies suggest that a number of different genes may be involved in determining a person�??s likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. Lupus is more common in young women. The treatment of lupus depends on the severity of the condition and what parts of the body are affected. Treatment may include acetaminophen, ibuprofen, antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as BLyS-specific inhibitors (Belimumab).

Wikipedia : 76 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1357)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 34.6 C1QA C4A DNASE1 DNASE1L3
2 neonatal lupus erythematosus 34.5 C4A TRIM21
3 pediatric systemic lupus erythematosus 34.1 C4A C4B STAT4
4 systemic lupus erythematosus 33.7 BANK1 C1QA C1QB C1QC C4A C4B
5 vitiligo-associated multiple autoimmune disease susceptibility 1 33.3 CTLA4 PDCD1 PTPN22
6 c1q deficiency 33.1 C1QA C1QB C1QC
7 glomerulonephritis 31.0 C1QB C1QC C4A C4B
8 autoimmune disease 31.0 CTLA4 FCGR2B IRF5 PDCD1 PTPN22 STAT4
9 primary biliary cholangitis 30.4 CTLA4 IRF5
10 inflammatory bowel disease 29.9 CTLA4 IRF5 PTPN22 STAT4 TLR5
11 lupus erythematosus tumidus 12.8
12 cutaneous lupus erythematosus 12.8
13 drug-induced lupus erythematosus 12.8
14 subacute cutaneous lupus erythematosus 12.8
15 lupus erythematosus panniculitis 12.8
16 discoid lupus erythematosus 12.8
17 systemic lupus erythematosus 1 12.7
18 systemic lupus erythematosus 2 12.7
19 systemic lupus erythematosus 10 12.7
20 systemic lupus erythematosus 6 12.6
21 systemic lupus erythematosus 9 12.6
22 systemic lupus erythematosus 11 12.5
23 neonatal systemic lupus erythematosus 12.4
24 systemic lupus erythematosus 3 12.4
25 systemic lupus erythematosus 4 12.4
26 systemic lupus erythematosus 5 12.4
27 systemic lupus erythematosus 7 12.4
28 systemic lupus erythematosus 12 12.4
29 chilblain lupus 1 12.4
30 hypertrophic or verrucous lupus erythematosus 12.3
31 systemic lupus erythematosus with hemolytic anemia 1 12.3
32 systemic lupus erythematosus 15 12.3
33 systemic lupus erythematosus with nephritis 1 12.3
34 systemic lupus erythematosus with nephritis 2 12.3
35 systemic lupus erythematosus with nephritis 3 12.3
36 systemic lupus erythematosus 8 12.3
37 systemic lupus erythematosus 13 12.3
38 systemic lupus erythematosus 14 12.3
39 discoid lupus erythematosus of eyelid 12.2
40 mixed connective tissue disease 11.8
41 antiphospholipid syndrome, familial 11.8
42 st. louis encephalitis 11.6
43 sjogren syndrome 11.6
44 macrophage activation syndrome 11.5
45 pure red-cell aplasia 11.5
46 complement component 2 deficiency 11.5
47 hypogonadotropic hypogonadism 11.5
48 retinal vasculitis 11.5
49 epidermolysis bullosa acquisita 11.5
50 pemphigus erythematosus 11.5

Graphical network of the top 20 diseases related to Lupus Erythematosus:



Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus

UMLS symptoms related to Lupus Erythematosus:


seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

GenomeRNAi Phenotypes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.1 C1QA TRIM21
2 Decreased viability GR00381-A-1 10.1 C1QA PDCD1 SNRPB
3 Decreased viability GR00381-A-2 10.1 C1QA
4 Decreased viability GR00381-A-3 10.1 C1QA PDCD1
5 Decreased viability GR00402-S-2 10.1 BANK1 C1QA C1QB C1QC C4A C4B
6 no effect GR00402-S-1 9.62 BANK1 C1QA C1QB C1QC C4A C4B

MGI Mouse Phenotypes related to Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 BANK1 C4B CR2 CTLA4 DNASE1 FCGR2B
2 homeostasis/metabolism MP:0005376 10.13 C1QA C4B CR2 CTLA4 DNASE1 FCGR2B
3 immune system MP:0005387 10.13 BANK1 C1QA C4B CR2 CTLA4 DNASE1
4 mortality/aging MP:0010768 9.77 C1QA C4B CR2 CTLA4 DNASE1 FCGR2B
5 liver/biliary system MP:0005370 9.7 C4B CTLA4 FCGR2B PDCD1 PTPN22 TLR5
6 renal/urinary system MP:0005367 9.32 C1QA C4B CR2 DNASE1 FCGR2B PDCD1

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 118-42-3 3652
3
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
5
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
7 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
9
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
10
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
14
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 356547-88-1 5957 10451420
15
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
17
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 124-94-7 31307
18
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21 Lifitegrast Approved Phase 4 1025967-78-5
22
4-Aminopyridine Approved Phase 4 504-24-5 1727
23
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
24
Bortezomib Approved, Investigational Phase 4,Phase 2 179324-69-7 387447 93860
25
Metformin Approved Phase 4 657-24-9 14219 4091
26
Calcitriol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 32222-06-3 5280453 134070
27
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
31
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 beta-endorphin Phase 4,Phase 2
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Adrenocorticotropic Hormone Phase 4,Phase 2
36 Melanocyte-Stimulating Hormones Phase 4,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Rosuvastatin Calcium Phase 4,Phase 3,Phase 2,Phase 1 147098-20-2
42 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
43 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 728)
# Name Status NCT ID Phase Drugs
1 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
2 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
6 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
7 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
8 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
9 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
10 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
11 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
12 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
13 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
14 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
15 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
16 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
19 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
20 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
21 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
22 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
23 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
24 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Participants With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
25 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
26 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
27 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
28 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
29 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
30 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
31 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
32 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
33 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
34 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Recruiting NCT02849782 Phase 4 Fampridine
35 Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis Recruiting NCT03214731 Phase 4 Artesunate
36 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
37 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
38 The Effect of Metformin on Reducing Lupus Flares Active, not recruiting NCT02741960 Phase 4 metformin;placebo
39 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
40 Safety and Immunogenicity of a Zoster Vaccine in SLE Active, not recruiting NCT02477150 Phase 4
41 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Active, not recruiting NCT03098823 Phase 4 RAYOS;Prednisone
42 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
43 Trial of Belimumab in Early Lupus Not yet recruiting NCT03543839 Phase 4
44 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
45 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
46 A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients Terminated NCT01316133 Phase 4 tacrolimus
47 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
48 Doxycycline Outcomes in Lupus Erythematosus Withdrawn NCT01014260 Phase 4 Placebo;Doxycycline
49 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
50 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

MalaCards organs/tissues related to Lupus Erythematosus:

41
T Cells, Skin, B Cells, Heart, Bone, Kidney, Endothelial

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 11139)
# Title Authors Year
1
Canine Cutaneous Lupus Erythematosus: Newly Discovered Variants. ( 30227971 )
2019
2
H-magnetic resonance spectroscopy: diagnostic tool in recurrent headache in systemic lupus erythematosus. A case report. ( 30425768 )
2019
3
Intestinal pseudo-obstruction as the initial manifestation of systemic lupus erythematosus. ( 30291036 )
2019
4
Activity and expression of E-NTPDase is altered in peripheral lymphocytes of systemic lupus erythematosus patients. ( 30409763 )
2019
5
mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b+Gr1+ cells. ( 30292636 )
2019
6
Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. ( 30159624 )
2019
7
Immunoglobulin G subclass 3 in ISN/RPL lupus nephritis classification
. ( 30431429 )
2019
8
Lupus Nephritis. ( 30454753 )
2019
9
"It's not lupus, it's your nails!" ( 30357846 )
2019
10
Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. ( 29951963 )
2018
11
Anti-tubulin-I+-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations. ( 29427009 )
2018
12
Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study. ( 29955369 )
2018
13
Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. ( 29979417 )
2018
14
The existential experience of everyday life with systemic lupus erythematosus. ( 29350776 )
2018
15
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
16
Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment. ( 28650277 )
2018
17
CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. ( 29728857 )
2018
18
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
19
Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity. ( 29976042 )
2018
20
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
21
Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot <i>et al</i>. ( 29934372 )
2018
22
Bronchiolitis obliterans organising pneumonia as an initial manifestation in a patient with systemic lupus erythematosus: a rare presentation. ( 29804073 )
2018
23
Limbic Encephalitis in Association with Systemic Lupus Erythematosus. ( 29780149 )
2018
24
Prevalence and factors associated with fatigue in female patients with systemic lupus erythematosus. ( 29439873 )
2018
25
Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. ( 29801110 )
2018
26
[Opportunistic infection in systemic lupus erythematosus patients: the disease spectrum and the characteristics of peripheral lymphocyte subsets]. ( 29325308 )
2018
27
Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol. ( 29782299 )
2018
28
Complement deficiency in pediatric-onset systemic lupus erythematosus. ( 29692593 )
2018
29
Association of angiotensin-converting enzyme insertion/deletion polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis. ( 29205894 )
2018
30
Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus. ( 29434811 )
2018
31
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. ( 29247540 )
2018
32
Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. ( 29336019 )
2018
33
Systemic Lupus Erythematosus Presenting as Longitudinally Extensive Transverse Myelitis and Nephritis: A Case Report. ( 29872583 )
2018
34
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
35
Diffuse alveolar haemorrage as initial presentation of systemic lupus erythematosus: a case report. ( 28592199 )
2018
36
Women who had appendectomy have increased risk of systemic lupus erythematosus: a nationwide cohort study. ( 29971583 )
2018
37
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. ( 29496481 )
2018
38
A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study. ( 29709947 )
2018
39
The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. ( 29796907 )
2018
40
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. ( 28659045 )
2018
41
Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. ( 29549933 )
2018
42
Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). ( 29121273 )
2018
43
Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. ( 28755788 )
2018
44
Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. ( 28480528 )
2018
45
CCR6<sup>+</sup>Th cell distribution differentiates systemic lupus erythematosus patients based on anti-dsDNA antibody status. ( 29441231 )
2018
46
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
47
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
48
Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood. ( 29868531 )
2018
49
Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. ( 29288864 )
2018
50
Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus. ( 29271374 )
2018

Variations for Lupus Erythematosus

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 C1QA C1QB C1QC C4A C4B CTLA4
2
Show member pathways
12.73 C1QA C1QB C1QC IRF5 TLR5
3 12.37 CTLA4 IRF5 PDCD1 PTPN22 STAT4
4
Show member pathways
11.93 C1QA C1QB C1QC C4A C4B
5 11.88 C1QA C1QB C1QC C4A C4B CR2
6
Show member pathways
11.76 C1QA C1QB C1QC C4A C4B CR2
7 11.6 C1QA C1QB C1QC C4A C4B
8
Show member pathways
11.46 C1QA C1QB C1QC C4A C4B CR2
9 11.15 C1QA C1QB C1QC
10 10.85 C1QA C1QB C1QC C4A C4B FCGR2B

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen trimer GO:0005581 9.33 C1QA C1QB C1QC
2 blood microparticle GO:0072562 9.26 C1QB C1QC C4A C4B
3 complement component C1 complex GO:0005602 8.62 C1QA C1QB

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.99 C1QA C1QB C1QC C4A C4B
2 inflammatory response GO:0006954 9.88 C4A C4B FCGR2B TLR5
3 immune system process GO:0002376 9.87 C4A C4B CR2 CTLA4 IRF5 PTPN22
4 complement activation GO:0006956 9.65 C1QA C1QB C1QC C4A C4B
5 complement activation, classical pathway GO:0006958 9.63 C1QA C1QB C1QC C4A C4B CR2
6 negative regulation of B cell proliferation GO:0030889 9.58 CTLA4 FCGR2B
7 negative regulation of immune response GO:0050777 9.57 CTLA4 FCGR2B
8 regulation of innate immune response GO:0045088 9.56 FCGR2B PTPN22
9 histone mRNA metabolic process GO:0008334 9.55 SNRPB SSB
10 regulation of type I interferon production GO:0032479 9.54 TREX1 TRIM21
11 DNA catabolic process, endonucleolytic GO:0000737 9.52 DNASE1 DNASE1L3
12 negative regulation of interleukin-6 secretion GO:1900165 9.51 BANK1 PTPN22
13 negative regulation of B cell activation GO:0050869 9.49 BANK1 FCGR2B
14 DNA catabolic process GO:0006308 9.48 DNASE1 DNASE1L3
15 neutrophil activation involved in immune response GO:0002283 9.46 DNASE1 DNASE1L3
16 positive regulation of apoptotic cell clearance GO:2000427 9.43 C4A C4B
17 regulation of complement activation GO:0030449 9.43 C1QA C1QB C1QC C4A C4B CR2
18 regulation of acute inflammatory response GO:0002673 9.4 DNASE1 DNASE1L3
19 regulation of neutrophil mediated cytotoxicity GO:0070948 9.37 DNASE1 DNASE1L3
20 innate immune response GO:0045087 9.28 C1QA C1QB C1QC C4A C4B CR2

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclease activity GO:0004518 9.5 DNASE1 DNASE1L3 TREX1
2 protein tyrosine kinase binding GO:1990782 9.37 BANK1 PTPN22
3 deoxyribonuclease activity GO:0004536 9.26 DNASE1 DNASE1L3
4 complement binding GO:0001848 9.16 C4B CR2
5 serine-type endopeptidase activity GO:0004252 9.02 C1QA C1QB C1QC C4A C4B
6 deoxyribonuclease I activity GO:0004530 8.96 DNASE1 DNASE1L3

Sources for Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....